Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 92d509822fdc15a4-LAX IP: 118.31.43.22 UTC time: 2025-04-08T22:00:22+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4